nsc-89199 has been researched along with Neoplasms* in 2 studies
*Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. [MeSH]
1 review(s) available for nsc-89199 and Neoplasms
| Article | Year |
|---|---|
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
The protein tyrosine phosphatase SHP2 encoded by Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Enzyme Inhibitors; Humans; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2022 |
1 other study(ies) available for nsc-89199 and Neoplasms
| Article | Year |
|---|---|
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.
Shp2 protein tyrosine phosphate (PTP) is a novel target for anticancer drug discovery. We identified estramustine phosphate as a Shp2 PTP inhibitor from the National Cancer Institute Approved Oncology Drug set. A focused structure-activity relationship study indicated that the 17-phosphate group is required for the Shp2 PTP inhibitor activity of estramustine phosphate. A search for estramustine phosphate analogs led to identification of two triterpenoids, enoxolone, and celastrol, having Shp2 PTP inhibitor activity. With the previously reported PTP1B inhibitor trodusquemine, our study reveals steroids and triterpenoids with negatively charged phosphate, carboxylate, or sulfonate groups as novel pharmacophores of selective PTP inhibitors. Topics: Antineoplastic Agents, Hormonal; Estramustine; Humans; Models, Molecular; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Structure-Activity Relationship; Triterpenes | 2011 |